HER2-NEGATIVE BREAST CANCER

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study tests whether adding the drug capivasertib to standard hormone therapy helps people with advanced HR+/HER2- breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib pl…

This study is for premenopausal women with a common type of breast cancer (HR+/HER2-). It tests a drug called elacestrant, given alone or with another drug (triptorelin), for 4 weeks before surgery. The goal is to see if the treatment lowers a marker of cancer growth (Ki67) in th…

This study tests if giving chemotherapy directly into the fluid around the brain (via a small device called an Ommaya reservoir) along with standard body chemotherapy works better than standard chemotherapy alone for people with HER2-negative breast cancer that has spread to the …

This early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check the drug's safety, find the right dose, and se…

This study is testing whether tirzepatide, a drug used for weight loss, can help people with early-stage hormone-positive breast cancer lose at least 5% of their body weight during their regular cancer treatment. About 40 participants will take the drug and be monitored for safet…

This study tests a drug called elacestrant against standard hormone therapy in 220 people with ER+/HER2- breast cancer whose blood tests show signs of cancer returning (ctDNA) but no visible spread. The goal is to see if elacestrant can delay or prevent distant metastasis. Partic…

This early study tests whether combining a dendritic cell vaccine (DC1) with the drug elacestrant is safe and doable for people with hormone-positive, HER2-negative breast cancer that has spread. About 18 participants will receive the treatment for 8 weeks. The goal is to see if …

This early-phase study is testing an experimental drug called DR-0202 in about 96 people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the best do…

This study is for women with ER+HER2- breast cancer who have already had radiation and now need a second lumpectomy. It tests whether giving another round of radiation to the same breast is safe and what side effects it may cause. The goal is to control the cancer and avoid a ful…

This study tests a device called TheraBionic P1 that uses radio waves to target cancer cells. It is given to people with early-stage, hormone-positive, HER2-negative breast cancer before their surgery. The goal is to see if the device can reduce the number of cancer cells left in…

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced HR+/HER2- breast cancer or other solid tumors that have spread. The main goal is to find the safest and most effective dose, either…

This study tests whether adding retinoic acid (a vitamin A derivative) to standard immunotherapy can help shrink or control HER2-negative breast cancer in people whose tumors stopped responding to immunotherapy alone. About 10 adults with advanced breast cancer will receive the c…

This study is for people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a common first treatment. The trial will test a combination of two drugs, fulvestrant and abemaciclib, after a short break from the previous treatmen…

This early-phase study is for people with metastatic HR+ HER2- breast cancer that has spread to the bone. Researchers want to find the best dose of the drug abemaciclib when given together with radiation and hormone therapy. The goal is to control the disease and manage side effe…

This study tests a new combination of drugs (alpelisib, L-NMMA, and chemotherapy) in people with a rare and aggressive type of breast cancer called metaplastic breast cancer that has spread or cannot be removed by surgery. The goal is to see if the combination is safe and can shr…

This early-phase trial tests an investigational vaccine made from a patient's own immune cells, designed to target two cancer-related proteins (HER2 and HER3). It is given directly into the tumor along with standard chemotherapy before surgery. The study includes 30 adults with e…

This study tests whether giving a single dose of radiation during breast-conserving surgery can lower the chance of cancer coming back and improve how the breast looks afterward. It involves 620 women aged 55 or older with early-stage, HER2-negative breast cancer. The approach co…

This study is for people with HER2-negative breast cancer that has spread to the brain. It tests whether combining radiation therapy with two drugs (anlotinib and a tubulin inhibitor) can help control the cancer in the brain. The goal is to see if this approach can delay the canc…

This study tests whether combining two drugs—elacestrant and trastuzumab deruxtecan—can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2-low) that no longer responds to standard hormone therapy or CDK4/6 inhibitors. About 65 participants will recei…

This early-phase study tests a new treatment for people with metastatic pancreatic or breast cancer that has stopped responding to standard therapies. The treatment combines two chemotherapy drugs with high-dose vitamins and a stem cell transplant to help the body recover. The ma…

This study tests whether adding the drug ribociclib to standard hormone therapy can prevent breast cancer from coming back in people whose cancer has already returned in the same area. About 200 adults with hormone receptor-positive, HER2-negative breast cancer will take part. Th…

This study tests a daily pill called (Z)-endoxifen, sometimes combined with a monthly shot (goserelin) that temporarily stops the ovaries from making estrogen. The goal is to see if this treatment can slow or stop the growth of estrogen-receptor-positive, HER2-negative breast can…

This early-phase study is testing a new drug called OP-1250 (palazestrant) combined with other targeted therapies for people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find the safest dose and understand side effects. About 190 adu…

This study tests whether adding everolimus to elacestrant works better than elacestrant alone for people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation). About 240 adults whose cancer has worsened after standard hormone therapy and CDK4/6 inhibitor…

This study looks at whether giving antibody-drug conjugates (ADCs) a second time is safe and effective for people with advanced breast cancer that has spread. About 160 adults who have already received ADCs will be enrolled. The goal is to see if the tumors shrink or stop growing…

This study tests a drug called sacituzumab govitecan, given before surgery, in people with localized triple-negative breast cancer. The goal is to see if it can eliminate all cancer in the breast and lymph nodes. Some participants may also receive pembrolizumab. The study involve…

This study is for women with an early, hormone-sensitive type of breast cancer that has a higher chance of coming back. It tests whether a blood test (ctDNA) can identify who can safely skip chemotherapy and instead take a targeted pill (dalpiciclib) plus hormone therapy. About 3…

This study tests whether a new drug (RLY-2608) combined with fulvestrant works better than another approved combination (capivasertib + fulvestrant) for people with advanced or metastatic HR+/HER2- breast cancer that has a PIK3CA mutation. About 540 adults whose cancer worsened a…

This study tests whether a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) can shrink or control tumors in people with advanced hormone receptor-positive, HER2-negative breast cancer. About 20 participants will receive the treatment, and researchers will me…

This early-stage study tests a new drug (BGB-21447) combined with standard hormone therapy, with or without another targeted drug, in people with HR+/HER2- breast cancer that has spread. The goal is to find safe doses and see if the combination can shrink tumors. About 120 adults…

This early-stage study tests a new drug, RLY-2608, designed to block a faulty protein in cancer cells with a specific gene change (PIK3CA mutation). It is for adults with advanced solid tumors or certain breast cancers that have not responded to other treatments. The study will t…

This study looks at whether giving hormone therapy before surgery helps women with a certain type of breast cancer (invasive lobular carcinoma) have cleaner surgical results. The goal is to see if this approach lowers the chance of cancer cells being found at the edges of removed…

This study tests whether giving two different antibody drug conjugates (Dato-DXd and T-DXd) one after the other can shrink tumors in people with HER2-negative metastatic breast cancer whose cancer has already progressed after prior antibody drug conjugate therapy. About 357 parti…

This study tests a new, non-invasive imaging device that uses light to monitor how breast tumors respond to chemotherapy. Researchers want to see if it can accurately predict when the cancer has been completely eliminated (called a complete pathological response). The study invol…

This study tests a decision aid for women aged 70 and older with early-stage, low-risk breast cancer. The tool helps them and their doctors discuss treatment options, aiming to reduce aggressive treatments like mastectomy or radiation when not needed. About 402 participants will …

This study is testing a blood test called DiviTum TKa to see if it can spot early signs that hormone-receptor-positive metastatic breast cancer is becoming resistant to treatment. About 100 people starting or changing their hormone therapy or CDK4/6 inhibitor drugs will give bloo…

This study looks at how well women with early-stage, hormone-positive breast cancer take their prescribed medications (aromatase inhibitors with or without abemaciclib). About 319 participants will be followed for 6 months to see if those on the combination therapy have lower adh…

This study is looking at a test called EndoPredict that helps doctors figure out the risk of breast cancer coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if the test can accurately identify who can safely skip ch…

This study aims to match breast cancer patients with the most effective experimental drugs based on their tumor's unique features. Up to 5,000 participants will receive standard chemotherapy plus an experimental agent before surgery. Researchers will use MRI scans, tissue, and bl…

This study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their normal care. Researchers want to see how long these treatments control the cancer in real-world settings. The goal is to gather information…

This study is looking at a specific type of breast cancer that has spread (metastatic) and is HER2-negative but has androgen receptors (AR-positive). Researchers want to see if a special PET/CT scan that detects a protein called PSMA can help predict which cancers will not respon…